Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AVBPVery BearishIndustry Newsnews

High materiality9/10

ArriVent’s FURVENT failure drives near-term AVBP weakness despite secondary signals

Oct 6, 2026, 2:59 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Primary endpoint failure in a pivotal trial overrides secondary signal gains, triggering a dramatic near-term equity re-rating. Historical analogs show biotech stocks fall sharply on primary-endpoint misses, with limited immediate upside unless meaningful data is disclosed or financing is secured.

AI summary

What happened, with direct paths to the underlying reporting

ArriVent BioPharma's FURVENT Phase 3 readout failed to hit the primary progression-free survival endpoint, sending AVBP to a fresh 52-week low with heavy volume. While secondary endpoints hint activity (high ORR and PFS signals), the miss undermines commercial prospects and raises questions about financing and strategic options for firmonertinib.

Phase 3 FURVENT failed to meet primary endpoint; AVBP slides on results.
Secondary endpoints show PFS/ORR benefits; data maturation ongoing.
240mg dose: PFS 11.0 months (blinded); ORR 60% in 240mg group.
Stock down 49% to $14.49; volume surges to 14.10M, new 52-week low.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

ArriVent’s FURVENT failure drives near-term AVBP weakness despite secondary signals

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session